In comparison analysis using lipid-lowering drug instruments previously reported, we also found that genetically proxied PCSK9 inhibition was causally associated with RCC risk in men [OR = 1.02 [95% CI, 1.00–1.04], P = 0.026] (Supplementary Table 18). Here, PCSK9 is linked to renal cell carcinoma.